4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,830.00
arrow_upward
+1.59%(+60.00) 1D
ኖቬም 12, 3:30:00 ከሰዓት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,790
High
JP¥3,835
Low
JP¥3,775
Mkt. cap
178.26 ቢ
Avg. vol.
87.26 ሺ
Volume
71.20 ሺ
Dividend
3.26%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.20
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,790
High
JP¥3,835
Low
JP¥3,775
Mkt. cap
178.26 ቢ
Avg. vol.
87.26 ሺ
Volume
71.20 ሺ
Dividend
3.26%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.20
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
Quartz
·
ከ14 ደቂቃዎች በፊት
Nvidia stock sinks after Jensen Huang resigns; S&P 500, Nasdaq fall
ChartMill
·
ከ1 ሰዓት በፊት
S&P 500 Premarket Losers Led by NVIDIA, Sandisk, and Super Micro on Nov. 12
Investopedia
·
ከ31 ደቂቃዎች በፊት
Stock Market Today: Nasdaq, S&P 500 Poised to Open Lower as Nvidia Plunges on News CEO Jensen Huang Is Stepping Down
Yahoo Finance
·
ከ1 ቀን በፊት
Stock market today: Dow, S&P 500 slip after CPI data raises Fed rate-hike bets
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp